enGene Holdings (ENGN) Stock Overview
Through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ENGN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
enGene Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.53 |
| 52 Week High | US$11.14 |
| 52 Week Low | US$2.65 |
| Beta | -0.26 |
| 1 Month Change | -3.07% |
| 3 Month Change | 131.79% |
| 1 Year Change | 11.80% |
| 3 Year Change | -16.41% |
| 5 Year Change | n/a |
| Change since IPO | -13.49% |
Recent News & Updates
Shareholder Returns
| ENGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 40.8% | 4.8% | -0.4% |
| 1Y | 11.8% | 16.7% | 14.0% |
Return vs Industry: ENGN exceeded the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: ENGN underperformed the US Market which returned 12.9% over the past year.
Price Volatility
| ENGN volatility | |
|---|---|
| ENGN Average Weekly Movement | 17.5% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ENGN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ENGN's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 57 | Ron Cooper | www.engene.com |
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
enGene Holdings Inc. Fundamentals Summary
| ENGN fundamental statistics | |
|---|---|
| Market cap | US$544.39m |
| Earnings (TTM) | -US$94.72m |
| Revenue (TTM) | n/a |
Is ENGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENGN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$94.72m |
| Earnings | -US$94.72m |
Last Reported Earnings
Jul 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 11.5% |
How did ENGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/14 19:57 |
| End of Day Share Price | 2025/11/14 00:00 |
| Earnings | 2025/07/31 |
| Annual Earnings | 2024/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
enGene Holdings Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jie Cheng | CGS International |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Michael Schmidt | Guggenheim Securities, LLC |